In December 2012, Sunshine Biopharma announced that it had achieved dramatic effects in Uterine Cancer using its Adva-27a compound. The studies were carried out in MES-SA/Dx5, a Uterine Sarcoma cell line that has become multidrug resistant through the use of a commonly administered chemotherapy drug, Doxorubicin. Adva-27a was able to efficiently kill these cells with an IC50 of less than 8 micromolar, a pharmacologically very favorable drug concentration.
In addition to Uterine Cancer, Adva-27a has been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for Pancreatic Cancer as part of the plans of positioning Adva-27a for clinical development for Pancreatic Cancer in parallel with the previously announced multidrug resistant Breast Cancer indication. The first U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
"We are very pleased that this testing indicated that our drug, Adva-27a, is effective against Uterine Cancer," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "In the U.S. alone, over 52,000 new cases of Uterine Cancer are diagnosed each year. "We are anxious to begin our clinical studies soon and look forward to the opportunity of providing a new treatment for Uterine Cancer patients worldwide," he added.
About The Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report
The following links provide more information about the Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014:
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.